medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2022, Number 4

<< Back Next >>

An Med Asoc Med Hosp ABC 2022; 67 (4)

Microbiome and chronic diseases

Salame KL, Flores AXA, Sánchez MGR, Vargas OIO, Vélez PM, Guillermo DJP

Language: Spanish
References: 80
Page: 284-292
PDF size: 290.66 Kb.


ABSTRACT

In recent years, special attention has been paid to the microorganisms that inhabit the human body. It used to be believed that these were mere guests. However, attention has been focused on studying the relationship between these microorganisms and human health. In this review article, we intend to expose the relationship between the microbiota and certain gastrointestinal, metabolic, cardiovascular, neuropsychiatric and allergic diseases, according to current evidence. We conducted a review in PubMed, with the MeSH terms "microbiome", "microbiota", "gastrointestinal disease", "metabolic disease", "Neuropsychiatry" and "allergy". We included articles in English and Spanish, published between 2000 and 2021, that were meta-analyzes, review articles, and clinical and experimental trials of greater relevance to fulfill the objective of this manuscript. The microbiome is essential to maintain a good health in human beings. Alterations in the microbiome can cause many diseases, from those related to the gastrointestinal tract to neuropsychiatric ones.


REFERENCES

  1. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006; 7 (7): 688-693.

  2. Biagi E, Nylund L, Candela M, Ostan R et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One. 2010; 5 (5): e10667.

  3. Bäckhed F, Fraser CM, Ringel Y, Sanders ME et al. Defining a healthy human gut microbiome: current concepts, future directions, and clinical applications. Cell Host Microbe. 2012; 12 (5): 611-622.

  4. Flint HJ. The impact of nutrition on the human microbiome. Nutr Rev. 2012; 70 Suppl 1: S10-S13.

  5. Yatsunenko T, Rey FE, Manary M.J et al. Human gut microbiome viewed across age and geography. Nature. 2012; 486: 222-227.

  6. Martinez I, Lattimer JM, Hubach KL et al. Gut microbiome composition is linked to whole grain-induced immunological improvements. ISME J. 2013; 7: 269-280.

  7. Backhed F. Host responses to the human microbiome. Nutr Rev. 2012; 70: S14-S17.

  8. Brandt LJ. American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol. 2013; 108: 177-185.

  9. Andoh A, Tsujikawa T, Sasaki M et al. Faecal microbiota profile of Crohn's disease determined by terminal restriction fragment length polymorphism analysis. Aliment Pharmacol Ther. 2009; 29: 75-82.

  10. Lee CJ, Sears CL, Maruthur N. Gut microbiome and its role in obesity and insulin resistance. Ann N Y Acad Sci. 2020; 1461 (1): 37-52.

  11. Zhao L. The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol. 2013; 11: 639-647.

  12. Huang YJ, Marsland BJ, Bunyavanich S, O'Mahony L et al. The microbiome in allergic disease: Current understanding and future opportunities-2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. J Allergy Clin Immunol. 2017; 139 (4): 1099-1110.

  13. Iannone LF, Preda A, Blottiere HM, Clarke G et al. Microbiota-gut brain axis involvement in neuropsychiatric disorders. Expert Rev Neurother. 2019; 19 (10): 1037-1050.

  14. Integrative HMP (iHMP) Research Network Consortium. The integrative human microbiome project. Nature. 2019; 569 (7758): 641-648.

  15. Marchesi J, Adams D, Fava F et al. The gut microbiota and host health: a new clinical frontier. Gut. 2016; 65 (2): 330-339.

  16. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011; 472: 57-63.

  17. Koeth RA, Wang Z, Levison BS et al. Intestinal microbiota metabolism of L carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013; 19: 576-585.

  18. Tang WH, Wang Z, Levison BS et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013; 368: 1575-1584.

  19. Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature. 2009; 457: 480-484.

  20. Le Chatelier E, Nielsen T, Qin J et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013; 500: 541-546.

  21. Qin J, Li Y, Cai Z et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490: 55-60.

  22. Karlsson FH, Tremaroli V, Nookaew I et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013; 498: 99-103.

  23. Fujimura KE, Sitarik AR, Havstad S et al. Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. Nat Med. 2016; 22: 1187-1191.

  24. Arrieta MC, Stiemsma LT, Dimitriu PA et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Sci Transl Med. 2015; 7: 307ra152.

  25. Hsiao EY, McBride SW, Hsien S et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013; 155: 1451-163.

  26. Lynch S, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016; 375: 2369-2379.

  27. Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012; 143: 913-6.e7.

  28. Hansen TH, Gobel RJ, Hansen T, Pedersen O. The gut microbiome in cardiometabolic health. Genome Med. 2015; 7: 33.

  29. De La Cochetiere MF, Durand T, Lalande V, Petit JC et al. Effect of antibiotic therapy on human fecal microbiota and the relation to the development of Clostridium difficile. Microb Ecol. 2008; 56: 395-402.

  30. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. Isme J. 2007; 1: 56-66.

  31. Lofmark S, Jernberg C, Jansson JK, Edlund C. Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes. J Antimicrob Chemother. 2006; 58: 1160-1167.

  32. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008; 3: 563-578.

  33. Chang JY, Antonopoulos DA, Kalra A, Tonelli A, Khalife WT, Schmidt TM et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis. 2008; 197: 435-438.

  34. Pham M, Lemberg DA, Day AS. Probiotics: sorting the evidence from the myths. Med J Aust. 2008; 188: 304-308.

  35. Surawicz CM, McFarland LV, Greenberg RN, Rubin M et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000; 31: 1012-1017.

  36. Stecher B, Barthel M, Schlumberger MC, Haberli L et al. Motility allows S. typhimurium to benefit from the mucosal defense. Cell Microbiol. 2008; 10: 1166-1180.

  37. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009; 136: 1979-1988.

  38. Lutgendorff F, Akkermans LM, Soderholm JD. The role of microbiota and probiotics in stress-induced gastrointestinal damage. Curr Mol Med. 2008; 8: 282-298.

  39. Hofer U, Speck RF. Disturbance of the gut-associated lymphoid tissue is associated with disease progression in chronic HIV infection. Semin Immunopathol. 2009; 31: 255-266.

  40. Kullberg MC, Andersen JF, Gorelick PL, Caspar P et al. Induction of colitis by a CD4+ T cell clone specific for a bacterial epitope. Proc Natl Acad Sci USA. 2003; 100: 15830-15835.

  41. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434.

  42. Packey CD, Sartor RB. Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases. Curr Opin Infect Dis. 2009; 22: 292-301.

  43. Canakis A, Haroon M, Weber HC. Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes. 2020; 27 (1): 28-35.

  44. Pimentel M, Lembo A. Microbiome and its role in irritable bowel syndrome. Dig Dis Sci. 2020; 65 (3): 829-839.

  45. Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007; 133: 24-33.

  46. Jeffery IB, O'Toole PW, Ohman L et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012; 61: 997-1006.

  47. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009; 104: 1033-1049.

  48. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011; 364: 22-32.

  49. Wang DQ, Cohen DE, Carey MC. Biliary lipids and cholesterol gallstone disease. J Lipid Res. 2009; 50 Suppl: S406-S411.

  50. Abeysuriya V, Deen KI, Wijesuriya T, Salgado SS. Microbiology of gallbladder bile in uncomplicated symptomatic cholelithiasis. Hepatobiliary Pancreat Dis Int. 2008; 7: 633-637.

  51. Capoor MR, Nair D, Rajni Khanna G, Krishna SV et al. Microflora of bile aspirates in patients with acute cholecystitis with or without cholelithiasis: a tropical experience. Braz J Infect Dis. 2008; 12: 222-225.

  52. White JS, Hoper M, Parks RW, Clements WD et al. Patterns of bacterial translocation in experimental biliary obstruction. J Surg Res. 2006; 132: 80-84.

  53. Lorenzo-Zuniga V, Rodriguez-Ortigosa CM, Bartoli R, Martinez-Chantar ML et al. Insulin-like growth factor I improves intestinal barrier function in cirrhotic rats. Gut. 2006; 55: 1306-1312.

  54. Zhao HY, Wang HJ, Lu Z, Xu SZ. Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis. 2004; 5: 64-67.

  55. Liu Q, Duan ZP, Ha DK, Bengmark S et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004; 39: 1441-1449.

  56. Ley RE, Backhed F, Turnbaugh P, Lozupone CA et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A. 2005; 102: 11070-11075.

  57. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444: 1022-1023.

  58. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE et al. The effect of diet on the human gut microbiome: a metagenomics analysis in humanized gnotobiotic mice. Science Transl Med. 2009; 1: 6ra14.

  59. Larsen N, Vogensen FK, van den Berg FW et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010; 5: e9085.

  60. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56: 1761-1772.

  61. Creely SJ, McTernan PG, Kusminski CM et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007; 292: E740-E747.

  62. Furet JP, Kong LC, Tap J et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010; 59: 3049-3057.

  63. Zhang H, DiBaise JK, Zuccolo A et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A. 2009; 106: 2365-2370.

  64. Li JV, Ashrafian H, Bueter M et al. Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. Gut. 2011; 60: 1214-1223.

  65. Liou AP, Paziuk M, Luevano JM Jr, Machineni S et al. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013; 5: 178ra141.

  66. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021; 19 (1): 55-71.

  67. Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol. 2019; 15 (11): 635-650.

  68. Brown CT, Davis-Richardson AG, Giongo A et al. Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS One. 2011; 6: e25792.

  69. Oresic M, Simell S, Sysi-Aho M et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med. 2008; 205: 2975-2984.

  70. Koren O, Spor A, Felin J et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci USA. 2011; 108: 4592-4598.

  71. Karlsson FH, Fak F, Nookaew I et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012; 3: 1245.

  72. Khanna S, Tosh P. A clinician's primer on the role of the microbiome in human health and disease. Mayo Clin Proc. 2014; 89: 107-114.

  73. Bolte ER. Autism and Clostridium tetani. Med Hypotheses. 1198; 51: 133-144.

  74. Sandler RH, Finegold SM, Bolte ER, Buchanan CP et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol. 2000; 15: 429-435.

  75. Nitschke A, Deonandan R, Konkle AT. The link between autism spectrum disorder and gut microbiota: A scoping review. Autism. 2020; 24 (6): 1328-1344.

  76. Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989; 299: 1259-1260.

  77. Noverr MC, Huffnagle GB. The "microflora hypothesis" of allergic diseases. Clin Exp Allergy. 2005; 35: 1511-1520.

  78. Finegold SM, Molitoris D, Song Y, Liu C, Vaisanen ML et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis. 200; 35: S6-S16.

  79. Niers L, Martin R, Rijkers G, Sengers F et al. The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy. 2009; 64: 1349-1358.

  80. Kopp MV, Hennemuth I, Heinzmann A, Urbanek R. Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of lactobacillus GG supplementation. Pediatrics. 2008; 121: e850-e856.



EVIDENCE LEVEL

III




2020     |     www.medigraphic.com